Compressive Optic Neuropathy

Etiology

CON arises when the optic nerve or its surrounding structures are subjected to sustained mechanical pressure. This compression can be due to intrinsic lesions of the optic nerve itself or extrinsic processes from adjacent orbital, intracranial, or vascular pathology. Chronic compression disrupts axonal transport, compromises vascular perfusion, and triggers secondary inflammatory cascades, ultimately leading to axonal degeneration, demyelination, and progressive visual loss.

Etiologies can be broadly divided into infectious, inflammatory, vascular, traumatic, neoplastic, osseous, and miscellaneous causes, each with distinct clinical and radiological profiles (see Tables 1 and 2). Recognition of the underlying etiology is crucial, as prognosis and therapeutic options vary significantly.

Infectious Causes

The following infectious causes of granulomatous or mass-like lesions may compress the optic nerve:

• Fungal infections: Aspergilloma is the most frequently implicated, especially in immunocompromised hosts. Chronic invasive fungal sinusitis can extend into the orbital apex, leading to optic nerve compression.[3][13]
• Tuberculosis: Orbital or intracranial tuberculomas may rarely exert pressure on the nerve.[14]

Clinicians should bear in mind that infectious CON often progresses rapidly and requires urgent antimicrobial and sometimes surgical decompression.

Inflammatory Causes

Several inflammatory diseases present with orbital or meningeal masses that cause optic nerve compression, including:

• Idiopathic orbital inflammation (orbital pseudotumor): These etiologies are characterized by diffuse infiltration of orbital tissues, occasionally encasing the optic nerve.[14]
• Thyroid-associated orbitopathy (Graves’ disease): Extraocular muscle hypertrophy (especially inferior and superior recti) can compress the optic nerve at the orbital apex, one of the most common causes of CON worldwide.[15][16][17]
• Sarcoidosis: This condition develops due to granulomatous involvement of the orbit, meninges, or optic nerve sheath.[18]
• IgG4-related disease: Pachymeningitis and orbital pseudotumor are increasingly recognized contributors.[19][20][21][22]

Vascular Causes

The following vascular malformations and aneurysms may cause a compressive effect:

• Intracranial aneurysms, particularly those of the internal carotid, anterior communicating, or ophthalmic arteries [23][24]
• Carotid-cavernous fistulas secondary to venous congestion and enlargement of orbital veins, resulting in secondary CON.[25]
• Venous malformations, varices, and lymphangiomas, producing intermittent compression, often exacerbated by Valsalva maneuvers [26][27]
• Dolichoectasia or ectatic carotid arteries (may exert mass effect at the optic chiasm or canal) [28][29]

Traumatic Causes

Traumatic etiologies that may lead to CON include:

• Orbital fractures with bony displacement impinging on the optic canal [30][31]
• Subperiosteal hematomas or orbital hematomas following trauma resulting in acute, sight-threatening CON [32][33]
• Postsurgical scarring or implants (rare)

Neoplastic Causes

Neoplasms represent the most common category of chronic CON, which usually manifests insidiously, with progressive visual decline and occasionally proptosis. These neoplastic etiologies include:

• Benign tumors: Meningiomas (optic nerve sheath meningiomas), schwannomas, cavernous hemangiomas, and dermoid cysts [34][35][36][37]
• Primary malignant tumors: Optic gliomas (especially in NF-1), lymphomas, sarcomas [38][39][40]
• Secondary tumors: Pituitary adenomas, craniopharyngiomas, and metastases from systemic cancers (breast, lung, prostate)

Osseous (Bone-Related) Causes

Bony disorders can narrow the optic canal, leading to chronic compression, including:

• Fibrous dysplasia: Abnormal bone remodeling can narrow the optic canal [41][42]
• Paget’s disease of bone: Expansile lesions affecting the skull base [43]
• Osteopetrosis: Thickened, sclerotic bones compressing the optic nerve canal [44][45]
• Osteomas and hyperostosis: Localized bony overgrowths [46]
• Langerhans cell histiocytosis: Lesions involving skull base bones [47]

Other Causes

• Mucoceles: Expansion of paranasal sinus mucoceles (commonly ethmoidal or sphenoidal) into the orbital apex [48][49][50][51]
• Granulomatous meningitis: Tuberculosis or fungal infections, encases the optic nerve [52]
• Postradiation fibrosis: Late complication of cranial radiotherapy

 Table 1. Etiologies of Compressive Optic Neuropathy

 Table 2. Distinctive Clinical and Imaging Features by Etiology

Additionally, the leading causes of CON can vary by region. In Western countries, neoplasms and thyroid-associated orbitopathy represent the most frequent etiologies, while in Asia and Africa, infectious processes such as aspergilloma and tuberculosis occur more commonly. Neoplastic and osseous causes typically produce a slowly progressive course, while trauma, hematomas, and infections more often result in acute or subacute presentations. Patterns of spread can also vary by etiology. Paranasal sinus disease frequently extends into the orbital apex, whereas pituitary and parasellar masses exert pressure on the optic chiasm before involving the optic canal.

These distinctions are clinically relevant. Early identification of CON remains essential, as sustained compression leads to irreversible optic atrophy. Furthermore, timely intervention with medical therapy or surgical decompression offers the potential to preserve or restore vision when initiated before permanent damage occurs.

Epidemiology

Overall estimates from reported cases of CON are 1.14 to 4 cases per 100,000 individuals per year. Gender, race, ethnicity, and age vary depending on the specific etiology.[53] Due to the numerous etiologies that can cause CON, the estimates of its incidence vary depending on the etiology.

Thyroid orbitopathy associated with Graves’ disease occurs with an incidence of 16 cases per 100,000 in females and 2.9 cases per 100,000 in males.[54][55] Craniopharyngioma demonstrates an incidence ranging from 0.5 to 2 cases per 100,000 persons annually.[56] Fibrous dysplasia affects approximately 1 in 5,000 to 10,000 individuals.[57]

Orbital hemangiomas account for 8% to 10% of benign tumors in the pediatric population, showing a marked female predominance with a ratio of 5 to 1.[58][59] Pituitary adenomas appear with a frequency of 10.5%, yet these tumors produce visual symptoms only when they enlarge sufficiently to compress the optic nerve or the optic chiasm.[60] Optic gliomas, primarily affecting children, represent 3% to 5% of pediatric tumors.[61] A cerebral aneurysm involving the internal carotid artery near the optic nerve carries a prevalence of 3%.[62][63]

CON is not a single disease but a final common pathway caused by a wide spectrum of orbital, intracranial, vascular, infectious, inflammatory, and osseous disorders. As such, the epidemiology of CON reflects the underlying etiologies rather than a unified disease entity. Nonetheless, population-level studies and disease registries provide important insights into its frequency, demographic distribution, and global variation.[53]

Global Burden

The precise global incidence and prevalence of CON remain undefined due to the diverse etiologies and variable diagnostic practices. Available data suggest that CON accounts for 5% to 15% of all optic neuropathies. In developed regions, neoplasms, eg, meningiomas, pituitary adenomas, and craniopharyngiomas, along with thyroid-associated orbitopathy, represent the leading causes. In low-income and middle-income countries (LMICs), particularly in South Asia and Africa, infectious processes such as invasive fungal sinusitis caused by Aspergillus or Mucor, and granulomatous diseases, including tuberculosis and sarcoidosis, occur more frequently.[64]

Age Distribution

In children, optic pathway gliomas—often linked with neurofibromatosis type 1—constitute the most common cause of CON, while craniopharyngiomas represent another important etiology, especially in late childhood and adolescence. Among young to middle-aged adults, thyroid-associated orbitopathy peaks in the third to fifth decade with a strong female predominance, and pituitary adenomas occur most often between ages 30 and 50. In older adults, meningiomas, particularly optic nerve sheath meningiomas, and metastatic disease appear more commonly after age 50 (see Table 4). Bony disorders, eg, Paget’s disease or osteopetrosis, usually present in middle-to-late adulthood.[65]

Sex Distribution

Thyroid-associated orbitopathy demonstrates a female-to-male ratio of approximately 5 to 6:1, and optic nerve sheath meningioma shows a ratio of 3 to 4:1. Pituitary adenomas display a slight male predominance in macroadenomas, while microadenomas occur more frequently in women. Trauma-related CON disproportionately affects males, consistent with global injury patterns. Gliomas, sarcoidosis, and infectious causes, eg, invasive aspergillosis, exhibit no significant sex bias (see Table 4).[66]

Epidemiology in Various Regions

Thyroid eye disease affects approximately 16 per 100,000 women and 3 per 100,000 men annually, with complications occurring in about 3% to 8% of cases. Pituitary adenomas account for 10% to 15% of intracranial tumors, and nearly 50% present with visual pathway compression. Meningiomas represent the most common primary intracranial tumor, with an incidence of 8 to 9 per 100,000 annually; optic nerve sheath meningiomas comprise about 2% of orbital tumors. Trauma-related CON, though uncommon, arises in 0.5% to 5% of closed head injuries, particularly when hematomas or fractures cause compression.[67]

In India and Southeast Asia, thyroid eye disease remains prevalent but often receives delayed treatment, resulting in higher rates of CON. Invasive fungal sinusitis, particularly aspergillosis and mucormycosis, disproportionately affects diabetic and immunocompromised patients. During the COVID-19 pandemic, thousands of mucormycosis-related CON cases were reported. In Africa, infectious etiologies, eg, tuberculosis and fungal sinusitis, contribute significantly due to higher endemic rates and limited access to specialty care. In Japan and East Asia, thyroid orbitopathy occurs less frequently than in Western populations, while orbital inflammatory disease and IgG4-related disease are more common (see Table 3).[68]

Patterns of Spread

Paranasal sinus disease, including mucoceles and invasive fungal infections, often extends into the orbital apex and compresses the optic nerve. Sellar and suprasellar tumors, eg, pituitary adenomas and craniopharyngiomas, primarily compress the optic chiasm and retrochiasmal pathways. Lesions of the orbital apex, including inflammation, lymphoma, and sarcoidosis, cause direct optic nerve compression. Bony canal lesions (eg, fibrous dysplasia and osteopetrosis) progressively narrow the optic canal.[69]

Natural History and Prognostic Relevance

Slowly progressive etiologies, including meningioma, thyroid eye disease, and fibrous dysplasia, provide a window for recognition and timely intervention. Rapidly progressive causes, including invasive fungal sinusitis, hemorrhage, and metastases, carry a high risk of irreversible blindness unless addressed with urgent treatment.

Table 3. Major Compressive Optic Neuropathy Etiologies in Different Regions

 Table 4. Demographic Patterns of Compressive Optic Neuropathy Etiologies

Pathophysiology

The optic nerve is part of the CNS. The mammalian CNS lacks the ability for regeneration and axonal growth. When the optic nerve is exposed to axonal damage, glial scar tissue forms, limiting the diffusion of growth factors.[1] Inhibitory proteins of myelin (eg, Nogo and myelin-associated glycoprotein), low expression of growth factors, and lack of laminin are also some factors that hinder the ability for axonal regrowth.[70] The more proximal the damage of the optic nerve is to the eye, the faster apoptosis of the retinal ganglion cells will occur. Apoptosis will lead to a cascade of events involving p53, which will cause further cell death. A CON can occur by compressing the vascular supply and causing ischemia to the nerve, or by directly causing a mass effect on the axons, thereby impairing axonal transport and signal transmission. The areas most susceptible to compression are located where the nerve passes through small bone structures, eg, the orbital apex and the optic canal. 

Optic nerve compression, observed in exophthalmos secondary to thyroid disease, results from the enlargement of extraocular muscles due to the proliferation of fibroblasts, increased extracellular matrix, and adipocyte proliferation and differentiation.[15][16] Furthermore, CON develops when mechanical pressure is exerted on the optic nerve or its vascular supply, disrupting its ability to transmit visual information effectively. The optic nerve is uniquely susceptible to compression because it traverses confined anatomical spaces (eg, the orbit, optic canal, and suprasellar cistern), where even small lesions can exert significant mass effect. The pathophysiology involves a combination of mechanical distortion, impaired axoplasmic transport, and vascular compromise.[53]

The first insult is often a disruption of axoplasmic flow within retinal ganglion cell axons. Orthograde (from retina to brain) and retrograde (from brain to retina) transport become impaired, leading to congestion, axonal swelling, and eventual stasis, which manifests clinically as visual field defects, particularly central, cecocentral, or junctional scotomas. If compression persists, the nerve fibers experience progressive degeneration.[71]

In parallel, compression may compromise the delicate vascular supply of the optic nerve. The optic nerve is nourished by branches of the ophthalmic artery, the central retinal artery, and the pial circulation. Sustained pressure reduces perfusion, creating zones of ischemia and hypoxia. This vascular insufficiency accelerates axonal injury, leading to functional deficits that may progress even with relatively mild mechanical pressure.[72]

Over time, the combined mechanical and ischemic insults lead to loss of retinal ganglion cell axons. Clinically, patients progress from early symptoms, eg, dyschromatopsia, relative afferent pupillary defect (RAPD), and subtle visual field loss, to more advanced features, including severe visual decline and optic disc pallor. Notably, the rate of progression varies with the nature of the compressive lesion; slow-growing meningiomas or pituitary adenomas often allow for partial adaptation, whereas rapidly expanding hematomas or aneurysms may cause abrupt and profound visual compromise. The natural history of CON follows a spectrum: initial axoplasmic stasis leads to vascular compromise, resulting in progressive axonal degeneration and ultimately, optic atrophy. Because axonal loss is irreversible, early recognition and timely decompression are essential to prevent permanent blindness.[4]

Histopathology

Histopathological changes in CON reflect the chronic mechanical stress exerted on the optic nerve fibers, their blood supply, and surrounding connective tissue structures. The primary pathological hallmark is axonal loss due to sustained compression, which leads to secondary degeneration of the retinal ganglion cells. This manifests as thinning of the retinal nerve fiber layer, ultimately progressing to optic atrophy if the underlying cause remains untreated.[73]

Microscopically, compressed optic nerves exhibit axonal degeneration and demyelination. Axons within the compressed segment appear attenuated and fragmented, and oligodendrocyte loss is observed, resulting in patchy demyelination. Chronic compression disrupts axoplasmic flow, causing intra-axonal accumulation of organelles and swelling proximal to the lesion. In advanced cases, the nerve parenchyma is replaced by fibrous gliotic tissue, reflecting irreversible scarring.[4]

Vascular compromise is a significant contributing factor. Compression of the pial vessels and central retinal artery branches leads to ischemic damage. Histological sections reveal thickened vessel walls, narrowed lumina, and perivascular gliosis, which supports the role of ischemia in disease progression. In some cases, especially with tumors (eg, meningiomas), a dense fibrous reaction in the optic nerve sheath further aggravates compression. The optic disc morphology also correlates with histopathology. Early stages may exhibit disc pallor with preserved cupping, whereas long-standing cases display sectoral or diffuse atrophy. Retrograde degeneration leads to the loss of retinal ganglion cells in the inner retina, which corresponds to the visual field defects observed clinically.[74]

Special stains and immunohistochemistry highlight glial proliferation (GFAP-positive astrocytes), loss of axonal markers (eg, neurofilament protein), and deposition of extracellular matrix components in chronic cases. Importantly, unlike glaucomatous optic neuropathy, the predominant mechanisms in CON are mechanical distortion and ischemia, rather than elevated intraocular pressure. Overall, the histopathological spectrum of CON ranges from reversible axonal edema in acute compression to irreversible axonal loss with gliosis in chronic cases, underscoring the importance of early diagnosis and decompression.[12]

Toxicokinetics

While CON is primarily structural in origin, toxicokinetic considerations become relevant when systemic or locally administered drugs and toxins interact with compromised optic nerve tissue. Toxicokinetics refers to the process by which substances are absorbed, distributed, metabolized, and excreted, ultimately influencing tissue exposure and toxicity. In CON, the restricted vascular supply and impaired axoplasmic flow caused by compression can alter the pharmacokinetics of neurotoxic or neuroprotective agents within the optic nerve microenvironment.[4]

Drug-Induced Potentiation of Compressive Optic Neuropathy

Certain medications, eg, ethambutol, isoniazid, linezolid, or amiodarone, are known to cause optic neuropathy. In a patient with existing compressive pathology (eg, from thyroid eye disease, meningioma, or aneurysm), reduced blood–nerve barrier integrity and impaired clearance mechanisms increase susceptibility to drug accumulation and toxicity. Toxicokinetics in these cases are altered by localized ischemia and edema, prolonging drug residence time within the optic nerve.[4]

Vascular-Toxic Interactions

Compression of the optic nerve sheath can compromise perineural vessels, altering perfusion and oxygen delivery. This reduced clearance capacity increases the exposure of the nerve to systemic toxins (eg, methanol metabolites, heavy metals), which, under normal circulation, may have been more efficiently metabolized or eliminated. Thus, compressive lesions can exacerbate the neurotoxic potential of systemically circulating agents.[6]

Implications for Neuroprotective Drugs

On the other hand, toxicokinetic barriers also limit penetration of protective drugs, eg, corticosteroids, anti-VEGF agents, or antioxidants. The fibrotic and compressed environment alters local drug distribution, necessitating higher or targeted delivery strategies (eg, periocular injections and sustained-release implants). Understanding toxicokinetics is crucial for balancing therapeutic benefits against the increased risk of neurotoxicity in compressed nerves.[10]

Clinical Relevance in India and Low-Income and Moderate-Income Countries

In regions with higher rates of tuberculosis and infectious orbital disease, ethambutol and linezolid are frequently prescribed. Patients with CON due to granulomatous inflammation or orbital tumors are therefore doubly at risk—both from structural compression and altered toxicokinetics of these drugs. Clinicians must remain vigilant about cumulative drug doses, treatment duration, and the potential synergistic harm when CON coexists with systemic therapy.[12]

History and Physical

Clinical History

Patients with CON usually present with chronic progressive vision loss that can be in 1 or both eyes. These patients can present with headaches, nausea, vomiting, diplopia, dyschromatopsia, exophthalmos, an afferent pupillary defect, photophobia, red eye, or unexplained weight loss. Sudden or rapid visual loss is rare except in cases caused by trauma. These cases are usually due to blunt trauma or a penetrating injury. The nerve can be injured at any location along its path, although the orbital apex and the optic canal are the most susceptible areas to damage.[75]

Obtaining a comprehensive history helps focus the broad differential diagnosis, including:

• Symmetric or asymmetric vision loss
• Slow versus rapid onset of visual loss
• Family history of cancer
• History of radiation therapy
• Cardiovascular risk factors that include hypertension, peripheral vascular disease, and tobacco use
• Metabolic disease
• Autoimmune history [76]

Patients with CON often present with a subacute or slowly progressive decline in visual function, although the onset may be acute in cases of trauma or vascular compression. A careful and detailed history is crucial for differentiating CON from other optic neuropathies, eg, those with inflammatory, ischemic, or toxic etiologies.[77]

Patients typically report a gradually worsening, painless loss of vision in 1 or both eyes. The progression may be asymmetric and is often associated with visual field defects such as central or cecocentral scotomas, altitudinal defects, or peripheral constriction, depending on the site of compression. Color vision loss, especially red desaturation, is an early and sensitive symptom. Diplopia may be reported if the compressive lesion also affects ocular motor nerves or extraocular muscles, as seen in thyroid orbitopathy or orbital tumors.

In cases of orbital or parasellar masses, patients may experience proptosis, periocular swelling, or facial numbness. Headache, particularly retro-orbital or periorbital pain, is more common in tumors, aneurysms, or inflammatory lesions, whereas thyroid-associated orbitopathy may present with a history of systemic hyperthyroidism. Traumatic causes are associated with a clear history of orbital or craniofacial injury. A family or personal history of neurofibromatosis, pituitary disease, or systemic malignancy may provide important diagnostic clues.[76]

Physical Examination

The hallmark finding in CON is optic nerve dysfunction, characterized by reduced visual acuity, impaired contrast sensitivity, and dyschromatopsia. Pupillary assessment may reveal a RAPD in unilateral or asymmetric cases. Clinical ophthalmic evaluation typically includes:

• Slit-lamp examination: This test evaluates the retina, retinal arteries and veins, cornea, fovea, optic cup.
• Tonometry: Intraocular pressure is assessed.
• Proptosis: Clincal assessment for the presence of unilateral or bilateral protrusion of the eyes.[78]
• Visual acuity testing: The Snellen chart is used to assess visual acuity at baseline and follow-up assessments; best corrected vision should be recorded.
• Color vision testing: Ishihara or Farnsworth-Munsell tests (evaluates if a color deficit is present); red desaturation is an early indicator.
• Pupillary examination: RAPD in asymmetric cases.
• Visual fields: Visual field testing differentiates central from peripheral visual loss. Automated perimetry (Humphrey 30-2, 24-2) or Goldmann perimetry detects early scotomas, bitemporal defects, and junctional scotomas.
• Fundus examination: Optic disc edema in acute lesions; temporal pallor or diffuse atrophy in chronic compression.
• Ocular motility assessment: Testing of extraocular eye movements helps identify restrictions or diplopia associated with orbital lesions.[79]

On fundus examination, early cases may show a normal disc (so-called "retrobulbar neuropathy"), while chronic compression often leads to optic disc pallor and atrophy. In some cases, particularly with orbital lesions, optic disc edema may be present initially. Visual field testing reveals defects corresponding to the site of compression, including junctional scotomas in parasellar tumors, bitemporal hemianopia in chiasmal compression from pituitary adenomas, or arcuate/peripheral defects in orbital mass lesions. Proptosis, lid retraction, or restrictive motility defects may be observed in thyroid eye disease and orbital tumors.

Cranial nerve involvement, eg, ophthalmoplegia (III, IV, VI), trigeminal sensory loss (V1 distribution), or Horner’s syndrome, suggests a lesion extending into the cavernous sinus or orbital apex. Palpation of the orbit may occasionally reveal firm masses in superficial lesions, while auscultation can detect bruits in carotid–cavernous fistula. Systemic examination findings, including goiter, café-au-lait spots, or lymphadenopathy, may aid in identifying underlying systemic disease.[80]

Clinical Relevance

A structured history and detailed physical examination not only establish the suspicion of CON but also provide essential localizing information (see Table 6). Identifying associated systemic conditions, the rate of progression, and the presence of red-flag features, eg, rapidly progressive vision loss, severe headache, or neurological deficits, guides urgent imaging and intervention. In India and other low- and middle-income settings, the delayed recognition of subtle early signs often results in advanced disease at presentation, underscoring the importance of meticulous history-taking and comprehensive physical examination in preventing irreversible blindness.[81]

Table 6. Clinical Findings in Compressive Optic Neuropathy

Evaluation

The evaluation of CON requires a structured, interprofessional approach combining clinical, laboratory, imaging, and functional tests to confirm the diagnosis, localize the lesion, and guide management (see Image. Compressive Optic Neuropathy Evaluation). The evaluation is guided by international standards while incorporating region-specific protocols.[82]

A comprehensive neurological examination, followed by a thorough ophthalmological evaluation, should be performed. The exam will provide a baseline visual acuity and allow the clinician to monitor for progression or improvement. The eye will have reduced visual acuity with CON. The eye can also exhibit a deficiency in color vision, known as dyschromatopsia, which can be evaluated using the Ishihara test plate. Proptosis or resistance to manual pressure suggests the presence of an intraorbital lesion. Ocular motility abnormalities are evaluated by assessing the function and coordination of the eye muscles. The optic disc can be atrophic, edematous, or appear healthy. Optociliary shunt vessels can be identified due to obstruction in the venous return from the orbit.[11]

Laboratory Studies

Laboratory studies should include complete blood count, comprehensive metabolic panel, lipid panel, thyroid-stimulating hormone (TSH), free thyroxine (T4), triiodothyronine (T3), luteinizing hormone, anti-thyroid antibodies, thyroid-releasing hormone, follicle-stimulating hormone, prolactin, adrenocorticotropic hormone, insulin growth factor-1, cortisol, bone-specific alkaline phosphatase, and prostate-specific antigen. The angiotensin-converting enzyme is usually elevated in more than half of the patients with active sarcoidosis.[83]

Inflammatory and autoimmune testing includes erythrocyte sedimentation rate (ESR), C-reactive protein, angiotensin-converting enzyme, antinuclear antibody, antineutrophil cytoplasmic antibody, and IgG4, which assist in diagnosing sarcoidosis, vasculitis, or IgG4–related disease. Endocrine evaluation incorporates thyroid-stimulating hormone, T4, T3, and thyroid-stimulating hormone receptor antibody for Graves orbitopathy, along with a pituitary hormone panel measuring prolactin, growth hormone, adrenocorticotropic hormone, and cortisol. Infectious assessment may involve fungal serology for aspergillosis, tuberculosis polymerase chain reaction, and syphilis screening when indicated. Cerebrospinal fluid analysis becomes necessary when granulomatous or carcinomatous meningitis is suspected.[84]

Imaging Studies

Imaging studies are the mainstay of CON diagnosis. Brain and orbit magnetic resonance imaging (MRI) scans provide detailed images of the optic nerves, parasellar region, and orbital contents. Therefore, MRI is the preferred modality for diagnostic evaluation. Fat suppression sequences are required to demonstrate enhancing lesions inside the orbit. Thin-slice MRI of the brain and orbits (1–2 mm) with gadolinium enhancement and fat suppression serves as the gold standard for evaluating CON. This modality effectively identifies meningiomas, gliomas, pituitary adenomas, craniopharyngiomas, orbital masses, and aneurysms. Optic nerve sheath meningiomas often display the characteristic “tram-track” or “doughnut” sign.[85]

Lesions involving the orbital bones should be examined using a computed tomographic (CT) scan of the head and orbit. CT demonstrates orbital fractures and concomitant injuries in traumatic cases. CT provides superior assessment of bony abnormalities, including fibrous dysplasia, osteoma, fractures, and osteopetrosis. Clinicians frequently employ CT when MRI is contraindicated or as a complementary tool in orbital trauma and the evaluation of calcified lesions.[86]

Ultrasonography can be used for intraorbital biopsy of anteriorly located lesions.[87] Angiographic studies are indicated when vascular causes are suspected, including aneurysms, carotid-cavernous fistulas, or ectatic internal carotid arteries.

Functional and Electrophysiological Tests

Visual evoked potentials (VEP) demonstrating delayed P100 latency or reduced amplitude suggest optic nerve dysfunction. Electroretinography (ERG) helps distinguish between retinal and optic nerve pathology.[88]

International and National Guidelines

The American Academy of Ophthalmology (AAO) Preferred Practice Patterns in Neuro-ophthalmology (2022) recommend MRI of the brain and orbits as the gold standard, in conjunction with visual field monitoring and endocrine/autoimmune evaluation in select cases. The European Neuro-ophthalmology Society (EUNOS) guidelines emphasize interprofessional collaboration, particularly in pituitary, orbital, and inflammatory disease. The All India Ophthalmological Society (AIOS) neuro-ophthalmology subspecialty group endorses early MRI, systemic evaluation for thyroid- and TB-related causes, and interprofessional tumor board discussions for neoplastic and vascular etiologies.[89]

Differential Diagnosis Exclusion

Noncompressive optic neuropathies—including toxic, nutritional, demyelinating, ischemic, and hereditary forms—must be excluded through targeted history, blood testing, and imaging correlation. Comprehensive evaluation of CON integrates clinical examination, visual function testing, MRI or CT imaging, systemic investigations, and electrophysiology. Guidelines consistently highlight MRI with contrast as the diagnostic standard, supplemented by endocrine and autoimmune testing when clinically appropriate. Early detection through this interprofessional approach remains critical for preventing irreversible optic nerve damage.[90]

Treatment / Management

Compressive Optic Neuropathy Management Approaches

The first step in the management of CON is to treat the underlying causative condition. Corticosteroids are beneficial for inflammation associated with CON, eg, in sarcoidosis and thyroid disease. For these conditions, withdrawal of the steroid treatment can cause acute deterioration of vision. Surgical orbital decompression can help to improve CON caused by thyroid ophthalmoplegia.[91][92][93] For tumors intimately attached to the optic nerve (eg, optic nerve meningiomas), surgery can cause further loss of vision. Radiation therapy is beneficial for aggressive recurrent tumors and those located in areas adjacent to cranial nerves and eloquent brain tissue. Radiotherapy can also be used for surgically difficult-to-resect tumors, such as those located in the cavernous sinus. Radiation can rarely cause irreversible optic nerve damage; therefore, this therapy must be used judiciously.(A1)

In traumatic cases, conservative treatment is appropriate in patients with mild deficits because spontaneous improvement is often possible. Steroids have no benefit for CON caused by trauma. Surgery is used for patients with radiological evidence of CON.[33][94] Direct compression of the optic nerve by bone fragments or a subperiosteal hematoma is usually treated surgically.[94][95] However, surgery carries the risk of complications such as postoperative cerebrospinal fluid leak and meningitis.[96](A1)

The management of CON depends on the underlying etiology, the severity of optic nerve compromise, and the patient's overall systemic condition (see Table 7). The primary goal of therapy is to relieve pressure on the optic nerve, preserve visual function, and address the causative pathology. Early diagnosis and intervention are crucial, as prolonged compression often leads to irreversible optic atrophy. Additionally, optimal management of CON requires coordinated care (Please refer to the Consultations section for more information on interprofessional management).

Medical Management

High-dose intravenous corticosteroids play a central role in treating inflammatory or infiltrative causes, eg, thyroid eye disease, sarcoidosis, and idiopathic orbital inflammation. These agents reduce edema and mass effect around the optic nerve, often improving vision in the acute phase. For IgG4-related disease, granulomatous disorders, or refractory thyroid orbitopathy, clinicians employ steroid-sparing immunosuppressants and biologic therapies, including rituximab, azathioprine, methotrexate, and mycophenolate mofetil. In infectious cases, eg, aspergilloma or mucormycosis, targeted antifungal therapy must be combined with surgical debridement to achieve disease control. Management of Graves’ orbitopathy may also involve systemic corticosteroids, orbital radiotherapy, and newer biologics (eg, teprotumumab), which have demonstrated efficacy in reducing compressive effects at the orbital apex.[97]

Surgical Management

Orbital decompression represents the standard of care in thyroid eye disease complicated by sight-threatening optic neuropathy. Techniques include medial wall, orbital floor, and orbital fat decompression, which can be performed through external or endoscopic approaches. Neoplastic etiologies, including meningioma, glioma, pituitary adenoma, craniopharyngioma, and metastatic tumors, often require surgical resection, with adjuvant radiotherapy in select cases. Functional endoscopic sinus surgery offers effective decompression for patients with mucoceles or paranasal sinus lesions that affect the optic nerve. For vascular lesions (eg, aneurysms), neurosurgical clipping or endovascular interventions—including coiling or stenting—can relieve optic apparatus compression. Traumatic hematomas or fractures occasionally demand urgent surgical repair to prevent irreversible optic nerve injury.[98]

Radiotherapy

Fractionated stereotactic radiotherapy or Gamma Knife radiosurgery may be considered for unresectable or residual tumors such as meningiomas, craniopharyngiomas, and pituitary adenomas. These techniques stabilize or improve vision in selected patients.[99]

Observation and Monitoring

Patients with mild compressive lesions and preserved vision may be managed conservatively under close surveillance. Monitoring strategies include serial visual field testing, optical coherence tomography to assess retinal nerve fiber layer thickness, and contrast-enhanced magnetic resonance imaging to detect progression. Any evidence of deteriorating visual function necessitates prompt escalation to medical or surgical intervention.[100](A1)

National and International Guidelines

The European Group on Graves’ Orbitopathy (EUGOGO) recommends immediate intravenous methylprednisolone in sight-threatening thyroid eye disease, followed by urgent orbital decompression if no improvement occurs within 1 to 2 weeks. The AAO advocates for an interprofessional approach that involves ophthalmology, neurosurgery, otolaryngology, and radiology. Contrast-enhanced MRI remains the preferred modality, and surgical decompression is advised for progressive vision loss unresponsive to medical therapy. The National Comprehensive Cancer Network (NCCN) emphasizes individualized management of neoplastic causes, with tumor boards often recommending multimodal treatment strategies that combine surgery, radiotherapy, and, when indicated, chemotherapy.[100](A1)

 Table 7. Etiology-Specific Treatment Approaches

Differential Diagnosis

Differential diagnoses (see Table 8) that should be considered when evaluating patients with suspected CON include:

• Glaucoma [101]
• Ischemic optic neuropathy [102]
• Retinal vein occlusion
• Multiple sclerosis
• Uveitis

When evaluating for the specific etiology, the following common disorders should be excluded, as their treatment management differs:

• Pituitary tumors
• Schwannoma
• Meningioma
• Aneurysm
• Arteriovenous malformation
• Lymphoma
• Sarcomas
• Metastasis
• Glioma
• Trauma
• Sarcoidosis [103]

Table 8. Differential Diagnosis of Compressive Optic Neuropathy 

Pertinent Studies and Ongoing Trials

The evidence base for managing CON has significantly expanded in the past 2 decades, with multiple observational studies, retrospective cohorts, and clinical trials evaluating treatment outcomes across infectious, inflammatory, vascular, and neoplastic causes. Much of the evidence stems from outcomes of surgical decompression, radiotherapy, and, more recently, combined multimodal approaches.

Surgical Decompression Studies

Several large case series and prospective cohorts have documented the role of orbital, optic canal, and intracranial decompression in CON. In thyroid eye disease–related conditions, randomized controlled trials (RCTs), such as the EUGOGO studies, have demonstrated that early decompression significantly improves visual acuity, color vision, and visual fields compared to conservative management. Endoscopic transnasal decompression has also been validated in multiple studies as a minimally invasive approach with reduced morbidity.[53]

Radiotherapy Outcomes

Radiotherapy has been evaluated extensively in compressive optic neuropathies secondary to meningiomas, lymphoma, and pituitary adenomas. Modern conformal radiotherapy and stereotactic radiosurgery (SRS) techniques, including Gamma Knife and CyberKnife, have shown tumor control rates exceeding 90%, with stabilization or improvement of vision in 60% to 80% of cases. Long-term follow-ups from institutions, eg, the Mayo Clinic and Johns Hopkins, confirm the durability of tumor shrinkage with a relatively low risk of radiation-induced optic neuropathy (RION) when fractionation and dose constraints are respected.[104]

Medical Therapy Studies

Glucocorticoids remain central for inflammatory causes such as sarcoidosis or idiopathic orbital inflammation. The CIRTED trial (UK, 2018) established the role of intravenous methylprednisolone as first-line treatment in thyroid-associated orbitopathy, showing superior outcomes over oral steroids. More recently, biologics, eg, teprotumumab (an IGF-1R inhibitor), have revolutionized CON management in thyroid orbitopathy, with phase 2 and 3 trials reporting dramatic improvements in proptosis, diplopia, and optic nerve compression relief.[105]

Ongoing Trials and Future Directions

Several ongoing clinical trials are addressing unresolved questions in CON management, including:

• Teprotumumab extension studies (OPTIC-X trial): assessing long-term efficacy and relapse rates
• Checkpoint inhibitors and immunotherapies: exploring their role in lymphoma- and sarcoma-related orbital CON
• Low-dose radiotherapy protocols: aiming to optimize tumor control while minimizing toxicity in meningiomas
• Advanced neuroimaging biomarkers: investigation of diffusion tensor imaging (DTI) and optical coherence tomography angiography (OCTA) as early predictors of therapeutic response [106]

Meta-Analyses and Guidelines

Recent meta-analyses (2020–2023) synthesizing outcomes from surgical, radiotherapeutic, and biologic interventions highlight the following:

• Surgery remains first-line in rapidly progressive CON.
• Radiotherapy is best suited for benign or malignant tumors with moderate growth rates.
• Medical therapies (particularly biologics) are transforming management in thyroid-associated cases.

International guidelines, including those from the European Society of Endocrinology and North American Neuro-Ophthalmology Society (NANOS), now emphasize individualized, etiology-specific management, supported by robust clinical evidence.[107]

Treatment Planning

Treatment Planning Overview

Treatment planning for CON demands a highly individualized and interprofessional strategy that balances vision preservation, tumor or lesion control, and reduction of treatment-related morbidity. The choice of modality depends on the underlying etiology—whether neoplastic, inflammatory, vascular, or infectious—as well as lesion size, anatomical location, and the rate of disease progression. Treatment planning for CON relies on advanced radiotherapy modalities, eg, IMRT, SRS, and PBT, supported by precise imaging-based delineation and interprofessional coordination. Therefore, careful integration of surgical, medical, and radiotherapeutic strategies maximizes local control and visual preservation while minimizing morbidity.[108]

Simulation and Imaging

High-resolution MRI with orbital and skull base protocols serves as the gold standard for defining the extent of optic nerve compression, perineural spread, and involvement of adjacent structures. CT complements MRI, particularly in cases with bony abnormalities, eg, fibrous dysplasia, Paget’s disease, or osteomas. For radiotherapy planning, MRI-CT fusion is essential for delineating the gross tumor volume (GTV) and clinical target volume (CTV) while sparing critical structures, including the optic chiasm and the contralateral optic nerve.[109]

Radiation Therapy Techniques

Conventional external beam radiotherapy, once delivered with lateral opposed fields, is now used less frequently due to higher toxicity. Three-dimensional conformal radiotherapy (3DCRT) shapes beams to the tumor while sparing adjacent structures and remains an option where advanced technology is unavailable. Intensity-modulated radiotherapy (IMRT) has become the gold standard in many centers, providing steep dose gradients and precise targeting of irregular lesions such as sphenoid wing meningiomas and pituitary adenomas, while reducing the risk of radiation-induced optic neuropathy. SRS techniques, including Gamma Knife, CyberKnife, and LINAC-based systems, achieve local control rates exceeding 90% for small to medium benign tumors (eg, meningiomas and schwannomas), as well as selected metastases. Proton beam therapy (PBT), with its Bragg peak property, is particularly advantageous in pediatric and recurrent cases by minimizing long-term radiation sequelae.[110]

Prescription (Dose and Fractions)

For benign tumors such as meningiomas and schwannomas, fractionated radiotherapy typically delivers 50 to 54 Gy in 25 to 30 fractions, while SRS protocols include 12 to 15 Gy in a single fraction or 21 to 25 Gy in 3 to 5 hypofractionated treatments. Pituitary adenomas are treated with 45 to 50 Gy in 25 to 28 fractions for fractionated radiotherapy or 12 to 20 Gy in a single fraction with SRS, depending on lesion size and proximity to the optic nerve. Malignant tumors require different regimens: lymphoma receives 24 to 36 Gy in 12 to 18 fractions, often combined with chemotherapy. In comparison, metastases may be treated with 30 Gy in 10 fractions or 15 to 21 Gy in a single SRS session. Repeat irradiation protocols mandate strict adherence to cumulative dose limits, with exposure to the optic nerve and chiasm kept below 55 Gy.[111]

Target Volume Delineation

The gross tumor volume corresponds to the visible lesion on MRI. The clinical target volume encompasses areas of potential microscopic spread or perineural invasion, while the planning target volume includes additional margins of 2 to 3 mm to account for setup variability and motion. Organs at risk, including the optic nerves, optic chiasm, brainstem, pituitary gland, and contralateral eye, must be contoured carefully with strict dose constraints to protect vision and neurological function.[112]

Interprofessional Integration

Surgical intervention often precedes or complements radiotherapy in rapidly progressive or vision-threatening cases, eg, urgent decompression in thyroid orbitopathy or orbital apex tumors. Medical therapies, including corticosteroids and biologics (eg, teprotumumab), are integrated into treatment for inflammatory etiologies. Radiotherapy is planned when surgery is contraindicated, incomplete, or associated with a high risk of recurrence.[113]

Follow-Up and Adaptive Planning

Ongoing ophthalmic evaluation, including visual acuity, visual field testing, and optical coherence tomography of the retinal nerve fiber layer, is essential throughout therapy. Radiological reassessment with MRI is typically performed at 3 to 6 months post-treatment to evaluate response. Adaptive planning may become necessary in cases with substantial lesion shrinkage or anatomical change, particularly during IMRT or proton therapy.

Toxicity and Adverse Effect Management

Management of Toxicities in Compressive Optic Neuropathy

The management of CON frequently involves surgery, radiotherapy, chemotherapy, or multimodal approaches, each carrying distinct toxicities. Early recognition of complications and proactive intervention play a central role in optimizing outcomes and preserving visual function. Toxicity management in CON requires anticipation, prevention, and prompt intervention. Advances, eg, IMRT, proton therapy, minimally invasive surgery, and biologic agents have significantly reduced the incidence of treatment-related complications. Nevertheless, vigilant interprofessional follow-up remains essential for preserving function and maintaining quality of life.

Surgical Toxicities

Optic nerve injury may occur during decompression or tumor resection, leading to worsening vision loss. Preventive strategies include intraoperative neuro-monitoring, meticulous microsurgical techniques, and neuronavigation. High-dose corticosteroids can be administered postoperatively to reduce edema. CSF leaks and meningitis, especially after skull base or orbital apex surgeries, require lumbar drainage, watertight dural repair, and prophylactic antibiotics. Injury to cranial nerves III, IV, or VI may result in ocular motility disturbances. Management options include prism therapy, botulinum toxin injection, or strabismus surgery for persistent diplopia.[114]

Radiation-Related Toxicities

Radiation-induced optic neuropathy (RION), a dose-dependent complication typically occurring at cumulative doses above 55 Gy, presents with sudden, irreversible vision loss. Preventive measures include strict adherence to dosage limits (≤54 Gy for optic nerve and chiasm), fractionation strategies, and advanced techniques, eg, IMRT or proton therapy. Once RION develops, therapeutic options remain limited, although hyperbaric oxygen and anti-vascular endothelial growth factor (anti-VEGF) therapy have been attempted. Retinopathy and maculopathy, particularly after stereotactic radiosurgery, may be treated with anti-VEGF injections or laser photocoagulation in ischemic cases. Cataract formation often develops as a delayed effect of orbital irradiation and can be managed with phacoemulsification and intraocular lens implantation. Lacrimal gland irradiation may lead to dry eye syndrome or keratopathy, which can be best managed with lubricants, punctal plugs, or topical cyclosporine.[115]

Medical Therapy Toxicities

Corticosteroids, commonly used in thyroid orbitopathy and inflammatory conditions, may produce Cushingoid features, diabetes, hypertension, osteoporosis, and ocular hypertension. Management strategies include tapering to the lowest effective dose, providing bone protection with calcium, vitamin D, and bisphosphonates, and monitoring intraocular pressure. Biologic agents (eg, rituximab and teprotumumab) may cause infusion reactions, hearing loss in the case of teprotumumab, and immune suppression. Preventive measures include premedication with antihistamines or corticosteroids, audiometric monitoring, and prophylaxis for opportunistic infections. Chemotherapy for lymphoma may result in myelosuppression, neuropathy, or systemic toxicities, managed with growth factor support, dose modifications, and close systemic monitoring.[116]

Systemic and Supportive Toxicities

Endocrine dysfunction may follow radiotherapy for parasellar tumors due to pituitary damage, necessitating hormone replacement therapy with thyroxine, hydrocortisone, sex hormones, or growth hormone. Neurocognitive decline, though rare in fractionated radiotherapy, may occur in pediatric patients or those receiving high-dose regimens. Management strategies include neurorehabilitation, cognitive therapy, and minimizing radiation dose to the hippocampi with advanced treatment planning.[4]

Preventive and Monitoring Strategies

Multimodal imaging, combining MRI and OCT, enables the early detection of optic nerve and retinal changes. Regular visual function testing, including visual fields and contrast sensitivity, supports early identification of deficits. Strict dose constraints combined with modern radiotherapy planning protect the optic nerve, chiasm, and retina from excessive radiation. Patient education remains essential, with counseling focused on early recognition of vision changes, diplopia, and systemic drug toxicities to allow timely intervention.[117]

Staging

While CON is not universally staged in the same structured way as neoplasms or vascular disease, several frameworks have been proposed to stratify disease severity and guide treatment. These staging systems are primarily based on functional visual outcomes, structural optic nerve damage, and neuroimaging findings, rather than a single uniform pathological criterion.

Functional Staging (Vision-Based)

CON staging based on function uses the following ophthalmic evaluation findings to stratify disease severity: 

• Stage 0 (preclinical/asymptomatic): Detected incidentally on imaging with no visual field defect, normal visual acuity, and no optic disc changes
• Stage I (early symptomatic): Mild visual field defect (central or paracentral scotomas, early arcuate defect), normal or slightly reduced visual acuity, subtle color vision loss
• Stage II (moderate): Significant visual field constriction, RAPD, and reduced contrast sensitivity. Optic disc pallor may begin to appear
• Stage III (advanced): Severe constriction of fields, marked optic atrophy, and reduced best-corrected visual acuity (<20/200 in severe cases)
• Stage IV (end-stage): No light perception or minimal residual light perception with complete optic atrophy [118]

Radiological Staging (Imaging-Based)

The following radiological staging is based on the site and degree of compression determined by MRI/CT evidence:

• Stage A (proximity): Lesion abutting the optic nerve or chiasm but without deformation
• Stage B (contact and deformation): Clear contact with optic nerve/chiasm with visible deformation
• Stage C (signal changes): Optic nerve demonstrates T2 hyperintensity (suggesting edema, ischemia, or demyelination)
• Stage D (atrophy): Chronic compression with optic nerve thinning and secondary changes in surrounding structures [119]

Disease-Specific Staging

Some conditions causing CON (eg, thyroid eye disease, optic nerve sheath meningioma) have their own staging systems that overlap with CON, including:

• Thyroid eye disease: The NOSPECS classification includes optic nerve dysfunction as a late-stage condition.
• Optic nerve sheath meningioma: Tumor volume and length of encasement on imaging help define progression and therapeutic thresholds.[67]

Proposed Composite Clinical-Radiological Staging

Several authors have suggested the following integrated staging system:

• Stage I (radiological): Lesion abutting optic nerve with no functional loss.
• Stage II (subclinical functional loss): Early color vision changes or subtle field defects, preserved acuity.
• Stage III (established functional loss): Clear field defect, RAPD, disc pallor, and documented compression.
• Stage IV (irreversible damage): Severe atrophy with profound functional loss, little chance of visual recovery even with decompression.[120]

Clinical Relevance of Staging on Management 

CON does not follow a universally standardized staging system comparable to those used for neoplasms or vascular diseases. However, several frameworks have been developed to help determine disease severity and identify optimal individualized treatment approaches. Generally, in early stages (0–I), management emphasizes observation and close monitoring, with surgical intervention considered if disease progression occurs. Moderate stages (II–III) often require stronger consideration for optic nerve decompression, radiation therapy, or targeted medical therapy, depending on the underlying etiology. End-stage disease (IV) shifts the focus toward preventing contralateral involvement, implementing visual rehabilitation strategies, and providing comprehensive patient counseling to support quality of life.[121]

Prognosis

The prognosis for CON depends on the underlying pathophysiology (vascular insufficiency or axonal damage) present and the duration from the time of presentation to the time of treatment. The recovery of visual symptoms typically correlates with the length of time between presentation and the time to perform the decompression. The consensus in the literature is that the earlier the decompression, the better the ultimate clinical outcome. Complete visual recovery has been seen as early as 1 week.[23] Slow progressive vision improvements have also been reported. More than half of the patients will improve clinically, irrespective of their preoperative visual status.[122] Early decompression is recommended, but good results can still be obtained even if decompression is performed in a delayed manner.[122]

Moreover, the prognosis for visual recovery varies significantly depending on the etiology causing the optic nerve compression. For tumor-related etiologies, negative predictive factors for visual improvement are the severity of visual loss, the presence of disc atrophy, recurrent tumor resection, tumor extension to the cavernous sinus, firm tumor consistency, absence of an arachnoid plane around the tumor, extensive tumor resection, and the longer the duration of visual loss. Overall, 60% of patients with tumors will experience some improvement after optic nerve decompression.[123]

Factors Influencing Prognosis

The prognosis of CON depends on a multitude of factors, including etiology, duration of compression, severity at presentation, and timing of intervention. Unlike other optic neuropathies, CON has a potentially reversible component if diagnosed early and treated promptly, since axonal dysfunction may precede irreversible axonal loss. These factors are associated with the following influences on an individual's prognosis :

• Etiology: Benign lesions (eg, meningioma, pituitary adenoma) generally carry a better prognosis than malignant or infiltrative causes (eg, lymphoma, metastatic tumors).
• Duration of compression: Prolonged compression leads to permanent axonal degeneration and optic atrophy. Early intervention before the development of pallor is associated with better visual recovery.
• Severity of visual loss at presentation: Patients presenting with mild to moderate visual loss or subtle field defects are more likely to recover compared to those with profound vision loss or severe optic atrophy.
• Treatment modality
• Surgical decompression: Decompression (eg, for pituitary adenoma, tuberculum sellae meningioma) often results in stabilization or improvement of vision, especially if performed early.
• Medical therapy: Conservative therapies (eg, corticosteroids in inflammatory or infiltrative conditions, radiotherapy for radiosensitive tumors) may also restore function.
• Timing: Delay in intervention significantly worsens outcomes.
• Age and general health: Younger patients tend to have better regenerative capacity and visual recovery.[103]

Expected Outcomes of Compressive Optic Neuropathy

Visual recovery occurs in approximately 60% to 80% of patients following timely decompression, with outcomes closely tied to the preoperative status. Visual field improvement may continue for several months after treatment. Incomplete recovery remains common when patients present with optic atrophy or long-standing compression, as irreversible ganglion cell loss limits visual potential.

Recurrence risk persists in cases of residual or recurrent tumors, where repeat compression may develop. Long-term surveillance, including neuroimaging and monitoring of visual function, is essential to detect early signs of recurrence.[122]

Long-Term Considerations

Permanent visual disability often develops in patients with late presentation, missed diagnosis, or aggressive pathology, and in some cases, vision loss becomes bilateral. Early recognition and timely intervention preserve functional vision, maintaining independence and quality of life. In contrast, delayed treatment frequently results in lifelong visual handicap.

Prognostic indicators (see Table 9) further refine expectations into the following:

• Favorable: Short duration of symptoms, absence of optic disc pallor, and mild to moderate visual field defects.

• Unfavorable: Severe baseline visual loss, established optic atrophy, older age, and malignant etiology.[124]

The prognosis of compressive optic neuropathy ranges from excellent to poor, depending on how early the diagnosis is made and treatment initiated. With prompt decompression or appropriate medical therapy, many patients can achieve significant visual improvement. However, delayed intervention leads to irreversible optic nerve damage, optic atrophy, and permanent visual disability.[125]

Table 9. Prognostic Indicators in Compressive Optic Neuropathy

Complications

Complications of Compressive Optic Neuropathy

CON may lead to complications, eg, papilledema, blurry vision, an afferent pupillary defect, diplopia, nausea, vomiting, permanent vision loss, impaired extraocular motility, and significant limitations in daily activities due to vision impairment.[126] Decompressive surgery, although effective in many cases, carries risks that include hemorrhage, infection, complete vision loss, prolonged intubation, coma, and death. Untreated or late-diagnosed CON can produce a broad spectrum of ocular, neurological, systemic, and treatment-related complications. These complications may arise from the disease itself or from therapeutic interventions (eg, surgery, medical therapy, or radiotherapy).[127] Consequently, early diagnosis and timely intervention remain essential to reduce the risk of these potentially devastating outcomes.

Ocular Complications

Permanent visual loss frequently develops as progressive and irreversible optic atrophy results from chronic compression, with complete blindness occurring in untreated cases. Visual field defects, including scotomas and hemianopic field loss, may persist or worsen despite decompression. These defects often result in the loss of binocular vision and severe impairment of quality of life.

Additionally, optic disc changes, including secondary optic atrophy with marked thinning of the retinal nerve fiber layer, remain common in advanced stages of the disease. Ocular motility disorders result from compression or infiltration of cranial nerves III, IV, or VI, or involvement of the cavernous sinus, producing diplopia and strabismus. Tumors involving the orbit or surgical manipulation may also cause proptosis and lagophthalmos, leading to exposure keratopathy and secondary corneal damage.[128]

Neurological Complications

Endocrine dysfunction frequently follows pituitary adenomas or their treatment, manifesting as panhypopituitarism, diabetes insipidus, or Cushing’s disease. Moreover, intracranial extension of aggressive or malignant lesions can affect adjacent brain structures, causing seizures, hemiparesis, or altered sensorium. Tumors that obstruct cerebrospinal fluid pathways may lead to hydrocephalus and increased intracranial pressure. Parasellar lesions often compress nearby cranial nerves (III, IV, VI, V1, V2), producing ophthalmoplegia, trigeminal neuropathy, or facial numbness.[129]

Treatment-Related Complications

Surgical complications include optic nerve injury during decompression, cerebrospinal fluid leakage, meningitis, hemorrhage, and postoperative visual decline due to ischemia or edema. Radiotherapy may cause delayed toxicities, eg, radiation-induced optic neuropathy, retinopathy, dry eye, cataracts, or secondary neoplasia with high cumulative doses. Furthermore, medical therapy also carries risks, including corticosteroids, which may lead to systemic complications, eg, weight gain, hypertension, hyperglycemia, osteoporosis, and immunosuppression, while targeted therapies for thyroid eye disease may produce systemic toxicities, including liver dysfunction and gastrointestinal intolerance.[130]

Psychosocial and Functional Complications

Vision loss often results in diminished productivity and impaired quality of life, affecting the ability to drive, read, and work. Psychological consequences, eg, anxiety, depression, and social isolation, are common in patients living with chronic visual disability. Many patients require long-term rehabilitation, including low-vision aids, structured follow-up, and coordinated interprofessional care to maintain function and independence.[131]